Suppr超能文献

突变不会停歇:结构化治疗中断会增加HIV-1耐药风险吗?

Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?

作者信息

Dorman K S, Kaplan A H, Lange K, Sinsheimer J S

机构信息

Department of Biomathematics, University of California, Los Angeles, California, USA.

出版信息

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):398-402. doi: 10.1097/00042560-200012150-00003.

Abstract

We use a mathematical model to study the dynamics of HIV-1 replication during structured treatment interruptions (STIs) in infected patients. The model predicts rapid viral rebound, restoration of a latently infected cell pool, and critically, partially resistant mutant rebound that may be missed because of high levels of wild type virus. Because partially resistant viruses are capable of mutating to full resistance, a substantial increase in their numbers represents a threat to therapeutic response durability. Compared with continued treatment, STIs may increase the chance of mutation to full resistance by several thousandfold.

摘要

我们使用数学模型来研究感染患者在结构化治疗中断(STIs)期间HIV-1复制的动力学。该模型预测病毒会迅速反弹,潜伏感染细胞库会恢复,并且至关重要的是,部分耐药突变体也会反弹,而这可能会因野生型病毒水平过高而被遗漏。由于部分耐药病毒能够突变为完全耐药,其数量的大幅增加对治疗反应的持久性构成威胁。与持续治疗相比,结构化治疗中断可能会使突变为完全耐药的几率增加数千倍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验